Why the ITC is in vogue for pharma patent disputes
09 May 2017
|
Natalie Rahhal, New York
The number of pharma patent complaints at the International Trade Commission was up greatly last year. Natalie Rahhal analyses what is driving this and what benefits the ITC brings for pharmaceutical companies
Data and practitioners suggest that
pharmaceutical companies are beginning to look to the
International Trade Commission (ITC) as an appealing alternate
venue for patent litigation.
Pharmaceutical and biotech companies have a well-documented
history of conservatism. This makes sense: according to...
Please
log in to read the rest of this article.
New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Already registered?
Please make sure you log in to read the rest of the article.
Log in
Join us now
Gain FREE access to up to five free articles when you register now. Join here